Immunic Eyes Key Data Readout From Multiple Sclerosis Trial in 2025 | NASDAQ:IMUX

Proactive InvestorsJan 7 22:15

D. Boral Capital Maintains Buy on Immunic, Maintains $17 Price Target

BenzingaJan 7 21:10 · Ratings

Press Release: Immunic Highlights 2024 Accomplishments and Upcoming Milestones

Dow JonesJan 7 19:30

Immunic CEO Dr Daniel Vitt on Successful 2024, With More to Come in the Year Ahead | NASDAQ:IMUX

Proactive InvestorsDec 13, 2024 21:00

Immunic CSO Discusses Breaking the IBD Stigma to Mark Crohn's and Colitis Awareness Week | NASDAQ:IMUX

Proactive InvestorsDec 2, 2024 17:15

B.Riley Financial Maintains Immunic(IMUX.US) With Buy Rating, Maintains Target Price $6

Futu NewsNov 26, 2024 14:32 · Ratings